Co-crystal screening of diclofenac was written by Aakeroy, Christer B.;Grommet, Angela B.;Desper, John. And the article was included in Pharmaceutics in 2011.Name: 4-Chloro-3,5-dimethyl-1H-pyrazole This article mentions the following:
In the pharmaceutical industry, co-crystals are becoming increasingly valuable as crystalline solids that can offer altered/improved phys. properties of an active pharmaceutical ingredient (API) without changing its chem. identity or biol. activity. In order to identify new solid forms of diclofenac, an analgesic with extremely poor aqueous solubility for which few co-crystal structures have been determined, a range of pyrazoles, pyridines, and pyrimidines were screened for co-crystal formation using solvent assisted grinding and IR spectroscopy with an overall success rate of 50%. The crystal structures of three new diclofenac co-crystals are reported herein: (diclofenac)·(2-aminopyrimidine), (diclofenac)·(2-amino-4,6-dimethylpyrimidine), and (diclofenac)·(2-amino-4-chloro-6-methylpyrimidine). In the experiment, the researchers used many compounds, for example, 4-Chloro-3,5-dimethyl-1H-pyrazole (cas: 15953-73-8Name: 4-Chloro-3,5-dimethyl-1H-pyrazole).
4-Chloro-3,5-dimethyl-1H-pyrazole (cas: 15953-73-8) belongs to pyrazole derivatives. Pyrazole is a weak base, with pKb 11.5 (pKa of the conjugated acid 2.49 at 25 °C).Pyrazole used as a ligand to prepare organometallic compounds. Pyrazoles can be selectively lithiated at different carbons and subsequently react with electrophiles depending on the substitution patterns.Name: 4-Chloro-3,5-dimethyl-1H-pyrazole
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics